A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05990127 by Akeso, with a registry enrolment figure of 642 participants, started 2023-11-14 and due to reach its primary completion in 2025-08-05. Interventions recorded: AK104; Tislelizumab; carboplatin; Pemetrexed; Paclitaxel. Conditions listed: Locally Advanced or Metastatic NSCLC. Primary outcome: Overall Survival(OS); Progression-Free Survival(PFS) by investigator(INV). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition)". Sites: China. No results are recorded here; the registry entry is the source.